JP2024514255A5 - - Google Patents
Info
- Publication number
- JP2024514255A5 JP2024514255A5 JP2023561005A JP2023561005A JP2024514255A5 JP 2024514255 A5 JP2024514255 A5 JP 2024514255A5 JP 2023561005 A JP2023561005 A JP 2023561005A JP 2023561005 A JP2023561005 A JP 2023561005A JP 2024514255 A5 JP2024514255 A5 JP 2024514255A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cdr
- acid sequence
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169335P | 2021-04-01 | 2021-04-01 | |
| US63/169,335 | 2021-04-01 | ||
| PCT/IL2022/050348 WO2022208505A1 (en) | 2021-04-01 | 2022-03-31 | Enhanced anti-hvem antibodies and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514255A JP2024514255A (ja) | 2024-03-29 |
| JP2024514255A5 true JP2024514255A5 (https=) | 2025-04-07 |
Family
ID=83458354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561005A Pending JP2024514255A (ja) | 2021-04-01 | 2022-03-31 | 増強された抗ｈｖｅｍ抗体及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240067742A1 (https=) |
| EP (1) | EP4320162A4 (https=) |
| JP (1) | JP2024514255A (https=) |
| KR (1) | KR20240047954A (https=) |
| CN (1) | CN117412990A (https=) |
| AU (1) | AU2022251320A1 (https=) |
| CA (1) | CA3213956A1 (https=) |
| IL (1) | IL307407A (https=) |
| WO (1) | WO2022208505A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3511343A1 (en) * | 2012-05-04 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| WO2014183885A1 (en) * | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
| CN105061597B (zh) * | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| MX2019007963A (es) * | 2017-01-06 | 2019-10-21 | Iovance Biotherapeutics Inc | Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf. |
| CN113194966A (zh) * | 2018-10-03 | 2021-07-30 | 柰裴斯生命科学公司 | 抗cd79抗体及其应用 |
| BR112021021645A2 (pt) * | 2019-04-29 | 2021-12-21 | 4C Biomed Ltd | Anticorpos anti-hvem e uso dos mesmos. |
| WO2022074648A1 (en) * | 2020-10-05 | 2022-04-14 | 4C Biomed Limited | Marker for response to pd-1/pd-l1 immunotherapy |
-
2022
- 2022-03-31 WO PCT/IL2022/050348 patent/WO2022208505A1/en not_active Ceased
- 2022-03-31 EP EP22779311.4A patent/EP4320162A4/en active Pending
- 2022-03-31 CA CA3213956A patent/CA3213956A1/en active Pending
- 2022-03-31 IL IL307407A patent/IL307407A/en unknown
- 2022-03-31 CN CN202280039545.6A patent/CN117412990A/zh active Pending
- 2022-03-31 AU AU2022251320A patent/AU2022251320A1/en active Pending
- 2022-03-31 KR KR1020237037195A patent/KR20240047954A/ko active Pending
- 2022-03-31 JP JP2023561005A patent/JP2024514255A/ja active Pending
-
2023
- 2023-10-02 US US18/375,657 patent/US20240067742A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7844558B2 (ja) | リンパ球における阻害経路の中和 | |
| JP6767362B2 (ja) | リンパ球における阻害経路の中和 | |
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| JP2012518425A5 (https=) | ||
| JP2022531242A5 (https=) | ||
| CN117024588A (zh) | 抗cd19抗体在制备白血病治疗药物中的用途 | |
| AU2018348431A1 (en) | Antibodies targeting CD137 and methods of use thereof | |
| JP2022548777A5 (https=) | ||
| WO2025246679A1 (zh) | 一种广谱中和冠状病毒的抗体及其应用 | |
| JP2022524204A (ja) | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 | |
| JP2023549555A5 (https=) | ||
| CN110713539B (zh) | 一种抗癌胚抗原的抗体及其制备方法和用途 | |
| US10689441B2 (en) | Anti—TLR4 antibodies and methods of use thereof | |
| JP2021528364A (ja) | 抗ｂｃｍａ抗体及びその用途 | |
| CN110862456B (zh) | 一种抗癌胚抗原的抗体及其制备方法和用途 | |
| CN113621065B (zh) | 靶向4-1bb的全人源抗体及其制备方法和应用 | |
| JP2024514255A5 (https=) | ||
| WO2012095432A2 (en) | Tlr3 binding agents | |
| WO2017021552A1 (en) | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders | |
| JP2022523145A5 (https=) | ||
| JP2023530997A5 (https=) | ||
| JP2024529907A5 (https=) | ||
| CN115386003B (zh) | 抗SARS-CoV-2鼠源单克隆抗体及其应用 | |
| WO2025140539A1 (en) | Ultrapotent broardly neutralizing antibodies against sars-cov-2 variants and methods of use thereof | |
| JP2024534806A5 (https=) |